舒巴坦-杜氯巴坦:一种治疗鲍曼不动杆菌-钙酸钙复合体(ABC)医院获得性细菌性肺炎和呼吸机相关细菌性肺炎的新型联合抗生素。

IF 2.6 4区 医学 Q3 INFECTIOUS DISEASES
Wissam K Kabbara, Elina Sadek, Hanine Mansour
{"title":"舒巴坦-杜氯巴坦:一种治疗鲍曼不动杆菌-钙酸钙复合体(ABC)医院获得性细菌性肺炎和呼吸机相关细菌性肺炎的新型联合抗生素。","authors":"Wissam K Kabbara, Elina Sadek, Hanine Mansour","doi":"10.1155/cjid/2001136","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam-durlobactam. <b>Summary:</b> Sulbactam-durlobactam is a recently approved antimicrobial combination of two <i>β</i>-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with <i>Acinetobacter baumannii</i>-calcoaceticus complex (ABC) in patients 18 years and older. Sulbactam is a direct antibacterial activity with high susceptibility to <i>A. baumannii</i> species. Durlobactam, diazabicyclooctane <i>β</i>-lactamase inhibitors possesses a broad-spectrum activity against Ambler class A, C, and D serine <i>β</i>-lactamases. This combination has been studied to overcome resistance to ABC species. Data were obtained from in vitro and preclinical studies as well as phase I, II, and III clinical studies published in English between 200t0 and January 2023. A phase II trial showed similar tolerability and pharmacokinetics parameters of sulbactam-durlobactam in patients with urinary tract infections to placebo. However, no ABC infections were included in the trial. ATTACK, a phase III clinical trial of sulbactam-durlobactam, studied the safety and efficacy of sulbactam-durlobactam in patients with ABC HABP/VABP and showed its noninferiority to colistin. Reported adverse events include anemia, elevated liver enzymes, hyperkalemia, headache, diarrhea, nausea, urticaria, and vascular pain. Sulbactam-durlobactam is a new <i>β</i>-lactamase inhibitors combination active against MDR Gram-negative bacteria including ABC. It is currently approved for the treatment of HABP/VABP caused by susceptible ABC strains.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2025 ","pages":"2001136"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11824839/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment of <i>Acinetobacter baumannii</i>-Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.\",\"authors\":\"Wissam K Kabbara, Elina Sadek, Hanine Mansour\",\"doi\":\"10.1155/cjid/2001136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam-durlobactam. <b>Summary:</b> Sulbactam-durlobactam is a recently approved antimicrobial combination of two <i>β</i>-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with <i>Acinetobacter baumannii</i>-calcoaceticus complex (ABC) in patients 18 years and older. Sulbactam is a direct antibacterial activity with high susceptibility to <i>A. baumannii</i> species. Durlobactam, diazabicyclooctane <i>β</i>-lactamase inhibitors possesses a broad-spectrum activity against Ambler class A, C, and D serine <i>β</i>-lactamases. This combination has been studied to overcome resistance to ABC species. Data were obtained from in vitro and preclinical studies as well as phase I, II, and III clinical studies published in English between 200t0 and January 2023. A phase II trial showed similar tolerability and pharmacokinetics parameters of sulbactam-durlobactam in patients with urinary tract infections to placebo. However, no ABC infections were included in the trial. ATTACK, a phase III clinical trial of sulbactam-durlobactam, studied the safety and efficacy of sulbactam-durlobactam in patients with ABC HABP/VABP and showed its noninferiority to colistin. Reported adverse events include anemia, elevated liver enzymes, hyperkalemia, headache, diarrhea, nausea, urticaria, and vascular pain. Sulbactam-durlobactam is a new <i>β</i>-lactamase inhibitors combination active against MDR Gram-negative bacteria including ABC. It is currently approved for the treatment of HABP/VABP caused by susceptible ABC strains.</p>\",\"PeriodicalId\":50715,\"journal\":{\"name\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"volume\":\"2025 \",\"pages\":\"2001136\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11824839/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/cjid/2001136\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Infectious Diseases & Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/cjid/2001136","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

目的:评价舒巴坦-杜氯巴坦的药理学、药代动力学、药效学、抗菌活性、疗效、安全性及监管现状。摘要:舒巴坦-杜罗巴坦是最近批准的两种β-内酰胺酶抑制剂联合抗菌药物,用于治疗18岁及以上患者与鲍曼不动杆菌-钙乙酸复合体(ABC)相关的医院获得性细菌性肺炎(HABP)和呼吸机相关细菌性肺炎(VABP)。舒巴坦是一种对鲍曼不动杆菌敏感的直接抗菌药物。Durlobactam,重氮杂环辛烷β-内酰胺酶抑制剂对Ambler a类,C类和D类丝氨酸β-内酰胺酶具有广谱活性。该组合已被研究用于克服对ABC种的抗性。数据来自于2000年至2023年1月期间以英文发表的体外和临床前研究以及I、II和III期临床研究。一项II期试验显示舒巴坦-杜氯巴坦在尿路感染患者中的耐受性和药代动力学参数与安慰剂相似。然而,没有ABC感染被纳入试验。舒巴坦-杜氯巴坦III期临床试验ATTACK研究舒巴坦-杜氯巴坦治疗ABC型HABP/VABP患者的安全性和有效性,显示其对粘菌素的非劣效性。报道的不良事件包括贫血、肝酶升高、高钾血症、头痛、腹泻、恶心、荨麻疹和血管疼痛。舒巴坦-杜氯巴坦是一种新的β-内酰胺酶抑制剂组合,对包括ABC在内的耐多药革兰氏阴性菌有活性。目前被批准用于治疗由易感ABC菌株引起的HABP/VABP。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment of Acinetobacter baumannii-Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

Purpose: To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam-durlobactam. Summary: Sulbactam-durlobactam is a recently approved antimicrobial combination of two β-lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years and older. Sulbactam is a direct antibacterial activity with high susceptibility to A. baumannii species. Durlobactam, diazabicyclooctane β-lactamase inhibitors possesses a broad-spectrum activity against Ambler class A, C, and D serine β-lactamases. This combination has been studied to overcome resistance to ABC species. Data were obtained from in vitro and preclinical studies as well as phase I, II, and III clinical studies published in English between 200t0 and January 2023. A phase II trial showed similar tolerability and pharmacokinetics parameters of sulbactam-durlobactam in patients with urinary tract infections to placebo. However, no ABC infections were included in the trial. ATTACK, a phase III clinical trial of sulbactam-durlobactam, studied the safety and efficacy of sulbactam-durlobactam in patients with ABC HABP/VABP and showed its noninferiority to colistin. Reported adverse events include anemia, elevated liver enzymes, hyperkalemia, headache, diarrhea, nausea, urticaria, and vascular pain. Sulbactam-durlobactam is a new β-lactamase inhibitors combination active against MDR Gram-negative bacteria including ABC. It is currently approved for the treatment of HABP/VABP caused by susceptible ABC strains.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
108
审稿时长
>12 weeks
期刊介绍: Canadian Journal of Infectious Diseases and Medical Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to infectious diseases of bacterial, viral and parasitic origin. The journal welcomes articles describing research on pathogenesis, epidemiology of infection, diagnosis and treatment, antibiotics and resistance, and immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信